أعرض في EDS

Her2 Testing recommendations in Australia

التفاصيل البيبلوغرافية
العنوان: Her2 Testing recommendations in Australia
المؤلفون: Colin J. Ades, M. Bilous, Margaret C. Cummings, Jane E. Armes, Paul R. McKenzie, Lisa Tan, Andrew S. Field, Robert Brown, Peter Robbins, Bridget Cook, Huw R.H. Llewellyn, Wendy Raymond, Richard Bell
المصدر: Pathology. 33:425-427
بيانات النشر: Elsevier BV, 2001.
سنة النشر: 2001
مصطلحات موضوعية: Oncology, medicine.medical_specialty, Receptor, ErbB-2, medicine.drug_class, medicine.medical_treatment, Mammary gland, Antineoplastic Agents, Breast Neoplasms, Biology, Antibodies, Monoclonal, Humanized, Monoclonal antibody, Pathology and Forensic Medicine, Trastuzumab, Internal medicine, medicine, Humans, skin and connective tissue diseases, neoplasms, In Situ Hybridization, Fluorescence, Carcinoma, Australia, Antibodies, Monoclonal, DNA, Neoplasm, Immunotherapy, medicine.disease, Immunohistochemistry, Metastatic breast cancer, medicine.anatomical_structure, In situ hybridisation, Immunology, Female, Breast carcinoma, Algorithms, medicine.drug
الوصف: HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data.
تدمد: 0031-3025
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c94ed0ff2b09a9eba52a34cbb9d263b0
https://doi.org/10.1080/00313020120083133
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....c94ed0ff2b09a9eba52a34cbb9d263b0
قاعدة البيانات: OpenAIRE
الوصف
تدمد:00313025